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HLA MATCHING AT DNA LEVEL AND ITS IMPACT ON THE OUTCOME OF
PEDIATRIC TRANSPLANTS FOR LEUKEMIA IN MULTI-RACIAL SINGAPORE
Tan, P.-L., Villegas, M.S., Chua, H.-C., Yeoh, A., Quah, T.-C. National
University Health System, Singapore, Singapore, Singapore
We retrospectively reviewed the outcome of hematopoietic stem
cell transplants (HSCT) in pediatric patients from a multi-racial
background with acute and chronic leukemia based on the degree
of HLA match at allelic/ DNA levels. We compared the rates of
transplant related mortality (TRM), graft versus host disease
(GVHD), relapse and overall survival (OS) in patients receiving re-
lated and unrelated donor HSCT with HLAmatch or mismatch do-
nors. Between January 1998 and October 2010, 56 HSCT were
performed in 52 patients whose median age was 110 (range, 12 –
226) months old. HLA match was defined as DNA match at 8 loci
(HLAA, B, C andDRB1*).Matching at DNA level became standard
from October 2004 and was available for 50 of the HSCT reviewed.
For the 6HSCTHLA typed prior to this time, related and unrelated
donor HSCT were assigned as match and mismatch, respectively.
HLA match grade of up to 4 alleles mismatches or a 1 antigen mis-
match was acceptable. Amongst the 56 HSCT, indications included
acute lymphoblastic leukemia (N 5 20), acute myeloid leukemia
(N 5 21), acute biphenotypic leukemia (N 5 4), chronic myeloid
leukemia (N 5 10) and juvenile myelomonocytic leukemia (N 5
1). Of all the HSCT, 20were related donor HSCT (11 bonemarrow,
8 peripheral blood) and 36 were unrelated donor HSCT (19 bone
marrow, 4 peripheral blood, 12 cord blood). At a median follow-
up of 1.44 (0.02 – 10.75) years, the results are shown in the table.Table 1. Results
Results
(N555)
MRD
(N517)
MMRD
(N53)
MUD
(N510)
(9 ASC + 1 CB)
MMUD (N525)
ASC
(N514)
CB
(N511)
TRM 6% (1/17) 0% 0% 0% 18% (2/11)
Acute
GVHD
grade
2 to 4
41% (7/17) 67% (2/3) 80% (8/10) 71% (10/14) 27% (3/11)
Chronic
GVHD
18% (3/17) 67% (2/3) 50% (5/10) 57% (8/14) 27% (3/11)
Relapse 24% (4/17) 0% 0% 14% (2/14) 36% (4/11)
Overall
Survival
76% (13/17) 67% (2/3) 100% (10/10) 71% (10/14) 82% (9/11)
*1 patient with missing data. MRD: matched related donor; MMRD:
mismatched related donor; MUD: matched unrelated donor; MMUD:
mismatched unrelated donor; ASC: adult stem cells (either bone mar-
row or peripheral blood stem cells); CB: cord bloodTwo-thirds of our patients lack suitably matched related donors. Of
all unrelated donor HSCT, 2/3 had HLA mismatch unrelated
HSCT: excluding CB recipients; the TRM was low; GVHD rates
were higher with correspondingly lower relapse rates compared to
patients who received HLA match related donor HSCT. Patients
who received HLA match unrelated donor typed at DNA level fare
the best.Table 1. Transplant Survival-Cord Blood
Survival >100 Days >1 Year >3 YEars
Related EFS 100% 100% 100%
Related OS 100% 100% 100%
Unrelated (UR) EFS 67% 60% 61%
UR OS 68% 66% 61%
UR Malignant EFS 70% 63% 57%
UR Malignant OS 72% 67% 57%
UR Non-malig. EFS 62% 55% 52%
UR Non-malig. OS 62% 63% 61%
UR Malig. EFS after 2002 80% 74% 74%
UR Malig. OS after 2002 83% 79% 74%283
DYSLIPIDEMIA FOLLOWING PEDIATRIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Marron, J.M.1, Kharbanda, S.1,2, Craveiro, L.2, Balise, R.R.3,
Agarwal, R.1,2 1Lucile Packard Children’s Hospital at Stanford Univer-
sity, Palo Alto, CA; 2Lucile Packard Children’s Hospital at Stanford Uni-
versity, Palo Alto, CA; 3Stanford University, Stanford, CA
Background: Children who receive solid organ transplants have
been shown to frequently develop dyslipidemias after transplant
due to the effect of immunosuppressive regimens on various lipid
metabolism pathways. Little data exists to date, however, regarding
the effect of hematopoietic stem cell transplantation (HSCT) onlipid profiles in the pediatric population, most of whom receive sim-
ilar immunosuppressive therapies to their solid organ counterparts.
Methods: Baseline total cholesterol and triglyceride concentrations
were collected just prior to transplant for 61 children who underwent
HSCT between 2000 and 2009 at Lucile Packard Children’sHospital.
Comprehensive lipidpanelswere thencollected at eachpatient’s annual
post-transplant follow-up visit. Age at the time of transplant ranged
from ten months to twenty years, and follow-up time ranged between
one andnineyears post-transplant. 59%ofpatientsweremale.Twopa-
tients required a second transplant. 74% of patients underwent alloge-
neic transplants; the remainder received autologous transplants. 55%of
allogeneic recipients developed acute graft-versus-host disease
(GVHD), and 36%developed chronicGVHDduring their post-trans-
plant course. Patients who developed GVHD were treated with ste-
roids and a calcineurin inhibitor for an extended length of time.
Results:Mean pre-transplant total cholesterol concentrations were
136 mg/dL, below the 20th percentile for US children and adoles-
cents. By four years post-transplant, triglyceride concentrations in-
creased by 30% (to 130 mg/dL) and total cholesterol by 39% (to
189 mg/dL) from pre-transplant values. This total cholesterol con-
centration is above the 80th percentile for US children and adoles-
cents. Between year one and year four post-transplant, low-density
lipoprotein concentrations increased by 33% to 117 mg/dL, which
is at the 85th percentile for US children and adolescents.
Conclusion:Dyslipidemias affect a significant proportion of pediat-
ric HSCT recipients. This is likely due at least in part to immuno-
suppressive medications, particularly in those with GVHD
requiring prolonged immunosuppressive treatment. The number
of affected individuals increases with time since transplant, placing
transplanted patients at increased risk for early cardiovascular dis-
ease. Further studies are necessary to determine if intervention, ei-
ther pharmacologic or otherwise, is advisable for HSCT recipients
in order to mitigate this increased risk.284
CORD BLOOD TRANSPLANTATION: 16 YEAR PEDIATRIC EXPERIENCE AT
A SINGLE INSTITUTION
Brown, B., Kempert, P., Chon, A., Taylor-Smith, L., Reyes, D.R.,
Ikeda, A., Moore, T.B. David Geffen School of Medicine at UCLA, Los
Angeles, CA
Background:Cord blood is increasingly being used as an alternative
stem cell source for hematopoietic stem cell transplantation
(HSCT). We report the experience from a single institution and
the impact of Center experience, improving supportive care, and in-
creasing choice of cord units banked on outcome over time.
Methods: A retrospective chart review was performed reviewing all
pediatric hematopoietic stem cell transplants over a 16 year period.
Results:Over a 16 year period 435HSCT’s were performed. Eighty
of these were performed using cord blood as the stem cell source.
Four were from related donors (RD) and 76 were from unrelated do-
nors (URD). Twenty sevenwere transplanted for non-malignant dis-
eases (NMD) (26 URD; 1 RD) and 53 with malignant disease (MD)
(50 URD; 3 RD). Patients transplanted with related donors for ma-
lignant (3) and non-malignant (1) conditions had EFS and OS of
100% and 100% respectively. Incidence of acute GVHD grade II-
IV was 50% and Grade III-IV was 0 with no chronic GVHD. Se-
venty-six patients were transplanted with unrelated donors using
TBI and non-TBI containing regimens depending on disease. Im-
munosuppression for the majority (83%) consisted of CSA with
S258 Poster Session Iprednisone. Patients werematched at 4 (9%), 5 (67%) or 6 (24%) of 6
loci (high resolution at DRB1). Incidence of acute GVHD grade II-
IV was 36% and grade III-IV was 21%. Chronic GVHDwas absent
in 88% of evaluable patients, but limited in 12% with none having
extensive cGVHD. Please see Table for survival data.
Conclusion: Cord blood transplant offers a viable alternative to
bone marrow as a source of hematopoietic stem cells for transplan-
tation. Over the 16 years that cord blood has been used at our insti-
tution, significant improvement in survival was appreciated over the
latter half of that period. This is most likely do to a number of factors
including transplant center experience, improvements in supportive
care, more cord units available to select from and better appreciation
of factors (such asminimumnumber of cells needed for engraftment)
important in choosing the optimal graft. These results compare
favorably with matched bone marrow transplant controls.285
DOES EARLY INITIATION OF THERAPEUTIC PLASMA EXCHANGE AFFECT
OUTCOME IN PEDIATRIC STEM CELL TRANSPLANT-ASSOCIATED
THROMBOTIC MICROANGIOPATHY?
Jodele, S.1, Laskin, B.L.2, Pinkard, S.L.3, Carey, P.M.3, Goebel, J.2,
Davies, S.M.1 1Cincinnati Children’s Hospital Medical Center, Cincin-
nati, OH; 2Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH; 3University of Cincinnati, Cincinnati, OH
Stem cell transplant (SCT)-associated thrombotic microangiop-
athy (TMA) is a serious complication leading to acute and chronic
kidney injury, often with high mortality. The diagnosis of TMA is
challenging, and its unclear pathogenesis limits development of op-
timal therapies. We retrospectively reviewed 10 patients with TMA
receiving therapeutic plasma exchange (TPE). Criteria for TMA
diagnosis included microangiopathy (anemia, thrombocytopenia,
elevated LDH, decreased haptoglobin, presence of schistocytes, neg-
ative DAT) and impaired renal function.
TMAwas diagnosed within 100 days post-SCT in 9 of 10 patients.
Three of 10 patients had renal biopsy-proven TMA. These biopsies,
even though challenging in SCT, aided in the decision to institute
therapy. Direct sequence analysis of the complement genes CH1,
CFH, MCP, CFB, and CFR5 was performed in 4 patients and was
normal. However, 2 of these 4 patients had detectable CFH autoan-
tibodies. IL-8 and IL-6 levels were elevated in the 4 patients tested
for plasma cytokines. Seven patients were on renal replacement ther-
apy (RRT) and 6 on ventilator support during TMA. Eight patients
received 2-4 weekly rituximab doses without full response and pro-
ceeded to TPE, while 2 started rituximab and TPE concomitantly.
Single volume daily TPE was initiated 4-73 days after TMA diagno-
sis, continued until resolution of microangiopathic anemia, and then
tapered off after a median of 35 TPE sessions (range 17-79).
Even though 9/10 patients showed laboratory resolution of micro-
angiopathic anemia duringTPE, only 5 patients survived at amedian
of 525 days post-SCT (range 217-777 days). The 5 survivors started
TPE a median of 17 days (range 4-25 days) after TMA diagnosis,
while the 5 patients who died startedTPE amedian of 32 days (range
17-73 days) after TMA diagnosis. Notably, 3 of the 5 survivors had
multiorgan failure at TMA diagnosis and completely recovered
with early institution of TPE. All survivors eventually had normal
creatinine off RRT. Conversely, the 5 patients who had late institu-
tion of TPE developed chronic renal dysfunction (n 5 1) or end-
stage renal disease (n 5 4) and died at a median of 334 days post
SCT (range 151-631 days). Our data suggest the survival benefit of
early TMA diagnosis and therapy with TPE and rituximab which
may work by removing CFH autoantibodies or endothelium damag-
ing cytokines. Larger, prospective studies are required to evaluate
the benefit of these therapies in TMA.286
IV BUSULFAN ADMINISTERED q12 VS q6 HRS DURING CONDITIONING
OF PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (AlloSCT)
RECIPIENTS HAS COMPARABLE PHARMACOKINETICS AND SIGNIFICANT
REDUCTION IN NURSING/PHARMACIST COSTS
LeGall, J.1, Milone, M.C.2, Waxman, I.M.1, Shaw, L.M.2,
Harrison, L.1, Duffy, D.1, Militano, O.1, Bhatia, M.1, Satwani, P.1,George, D.1, Garvin, J.H.1, Bradley, M.B.1, van de Ven, C.1,
Cairo, M.S.1,3,4 1Columbia University, New York, NY; 2University of
Pennsylvania, Philadelphia, PA; 3Columbia University, New York, NY;
4Columbia University, New York, NY
Inaccurate busulfan dosing during AlloSCT conditioning can re-
sult in graft failure or regimen-related toxicity (Andersson, BBMT,
2009). IV busulfan divided q6hrs is safe and effective in pediatric Al-
loSCT recipients at a dose of 4 mg/kg/day in patients# 4 yrs old and
at a dose of 3.2 mg/kg/day in patients . 4 yrs old (Wall et al, PBC,
2010). Less frequent dosing regimens are attractive for the possibility
of cost-effectiveness, but data is limited on comparing q12 to q6hr
infusions of IV busulfan in pediatric AlloSCT recipients.
We compared two cohorts of pediatric AlloSCT recipients receiv-
ing IV busulfan during conditioning. Cohort A received IV busulfan
q6hr x 16 doses and cohort B received IV busulfan q12hr x 8 doses
(age # 4yrs received 4.0 mg/kg/day; age . 4yrs received 3.2 mg/
kg/day). Busulfan levels were obtained at 1, 2, 3, 5, 6 and 8 hours after
the first dose and measured by gas chromatography – mass spectros-
copy (GC-MS) of heparinized plasma. The area under the curve
(AUC) was calculated by a 1-compartment modeling system. Pa-
tients in cohort B were monitored throughout AlloSCT for develop-
ment of moderate to severe hepatic veno-occlusive disease after
administration of IV busulfan. Finally, the savings of the q12 vs
q6hr dosing interval were estimated based on pharmacist/nurse sal-
ary and difference in the frequency of IV busulfan administration be-
tween the two cohorts.
In comparing cohort A (q6hr; n5 89; mean age 7.9 yrs) vs cohort
B (q12hr; n 5 38; mean age 8.7 yrs) there was no statistically signif-
icant difference in the volume of distribution (Vd(L)), half-life (min),
or clearance (Cl (ml/min/kg)).
Cohort A Cohort B
Q6 IV Bu Q12 IV Bu P valuesN 89 38 N/A
Age (yrs) 7.9 ± 6.9 8.7 ± 7.6 0.586
Weight (kg) 30.91 ± 24.6 28.2 ± 19 0.509
Vd (L) 20.6 ± 16.6 19.4 ± 13.7 0.676
Half-life (min) 132.0 ± 31.1 129.10 ± 38.15 0.678
Cl (ml/min/kg) 3.6 ± 0.9 4.0 ± 1.5 0.215
AUC (mmol *min/L) 1077 ± 352 1886 ± 420 <0.0001
Salary Cost ($USD/pt) $3,413 $1,733 N/AAs expected, there was a significant increase in the AUC in cohort B
(q12hr) vs cohort A (q6hr) (18866420 vs 10776352 mmol*min/L; p
\0.0001). Within cohort B (q12hr) there was only a 1/38 incidence
of moderate to severe VOD. Based on bedside RN salary of $40/hr
and pharmacist salary of $60/hr, a cost savings of $1,680/patient
was estimated with q12 vs q6hr IV busulfan dosing.
In summary, IV busulfan q12 vs q6hr dosing during conditioning
of pediatric AlloSCT recipients results in comparable busulfan Vd,
half-life, and Cl and, as expected, a significant increase in AUC. Fur-
thermore, IV q12hr busulfan results in a very low incidence of VOD
in pediatric AlloSCT recipients. Finally, a significant cost reduction
with decreased nursing and pharmacist costs can be achieved with
q12hr administration of IV busulfan.287
UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR
CHILDREN WITH b-THALASSEMIA MAJOR
Shah, S.A., Beniwal, S.K., Shah, K.M., Patel, K.A., Patel, K.M.,
Shah, P.M. Gujarat Cancer and Research Institute, Ahmedabad, Gujarat,
India
Background: Beta-thalassemia major, one of the most prevalent he-
moglobinopathies throughout the world, can be cured by allogeneic
stem cell transplantation. Many patients, however, lack a suitably
matched related sibling donor. Unrelated umbilical cord blood
can be used as an alternative stem cell source for these patients.
This report describes transplantation of 7 children with beta-thalas-
semia major using partially HLA-matched unrelated umbilical cord
blood.
Methods:Conditioning included busulfan 16 mg/kg (day -10 to -7),
cyclophosphamide 200 mg/kg(day -5 to -2), fludarabine 90 mg/kg
